Login to Your Account



CEO Spills Exon-Skipper News: Sarepta DMD Filing Next Year

By Randy Osborne
Staff Writer

Wednesday, July 24, 2013
us_resized.jpg

In Wall Street's view, the outcome of another meeting between the FDA and Sarepta Therapeutics Inc. apparently did not bring enough about the path to a new drug application (NDA) filing for eteplirsen, the exon-skipping therapy for Duchenne muscular dystrophy (DMD).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription